This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Incyte's CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

Incyte Corporation (INCY)

Morgan Stanley Healthcare Conference Call

September 12, 2012 10:55 am ET


Paul A. Friedman – President and Chief Executive Officer

David C. Hastings – Executive Vice President, Chief Financial Officer


David Friedman – Morgan Stanley & Co. LLC


David Friedman – Morgan Stanley & Co. LLC

All right. I think we will get started here and thanks everyone for joining us. I’m Dave Friedman, one of the Biotech Analyst. And in terms of personal and research disclosures, you can look at And I’m joined happily up here by the team from Incyte on the far side Dave Hastings, Chief Financial Officer and then on the near side Paul Friedman, and the relation President and CEO.

And we’d look for this to be as interactive as possible, so anyone should please feel free to raise your hand and shout out, and we’ll make sure we can get your questions asked. So thank you both again for joining us and I think we can just jump right in. You guys relatively recently have had a drug approved for a rare blood diseases, and so maybe you can just talk about the drug, the approval and how the commercial roll out has gone so far.

Paul A. Friedman

Sure. So the drug is JAKAFI, generic name ruxolitinib. It is an inhibitor of two kinases, in a family of kinases known as Janus associated kinase. They are JAK1, JAK2, JAK3 and Tyk2, were all related and a family of enzymes. Our compound inhibits JAK1, and JAK2, but not JAK3, and inhibits Tyk2 to a significantly less degree than JAK1 and JAK2.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs